 Connection
Kirk Hansen to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications Kirk Hansen has written about Drug Screening Assays, Antitumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.092 |
|
|
|
-
Nishida-Aoki N, Zhu S, Chan M, Kang Y, Fujita M, Jiang X, McCabe M, Vaz JM, Davidson NE, Ghajar CM, Hansen K, Welm AL, Pillarisetty VG, Gujral TS. Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Cell Rep Med. 2025 Oct 21; 6(10):102357.
Score: 0.055
-
Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. J Med Chem. 2019 11 27; 62(22):10182-10203.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|